1265323-68-9

Upstream product

• 1236188-83-2 3-phenyl-4-(trifluoromethyl)isoxazole-5-carbonyl fluoride 
• 1265323-44-1 (Z)-N'-hydroxy-4-vinylbenzimidamide 
• 1236188-80-9 3-phenyl-4-(trifluoromethyl)isoxazole-5-carboxylic acid 
• 1236188-79-6 (3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)methanol 
• 932-90-1 syn-benzaldehyde oxime 
• 934-16-7 phenylhydroxamoyl chloride 

Downstream Products

• 1265324-39-7 (R)-3-(4-(oxiran-2-yl)phenyl)-5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazole 
• 1265324-40-0 (S)-3-(4-(oxiran-2-yl)phenyl)-5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazole 
• 1265322-67-5 2-(1-((S)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)-2-methylpropanoic acid 
• 1265322-49-3 3-(1-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidin-3-yl)propanoic acid 
• 1265322-35-7 2-(4-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)morpholin-2-yl)acetic acid 
• 1265322-33-5 5-hydroxy-1-(2-hydroxy-2-(4-(5-(3-phenyl-4-(trifmoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethyl)piperidine-3-carboxylic acid 
• 1265322-31-3 2-(3-(2-hydroxyethyl)piperidin-1-yl)-1-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethanol 
• 1265322-29-9 2-(3-(hydroxymethyl)piperidin-1-yl)-1-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)ethanol 
• 1265323-69-0 3-(4-(oxiran-2-yl)phenyl)-5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazole 

Relevant academic research and scientific papers

SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS

Disclosed are compounds of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is formula (II) Q is a substituted 5-membered monocyclic heteroaryl group; W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.